FinancialReconSpine

Implanet reports Q1 2020 revenue of €1.6 million

Bordeaux, Boston, April 21st, 2020 – 5:45pm CEST: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral and knee-surgery implants, today announced its revenue for the first quarter of 2020.

Before the impact of Covid-19, Implanet had a brisk start to the year and posted revenue of €1.51 million for the period ended March 16th, up from €1.31 million over the same period in 2019, representing double-digit growth of 15%.

*Unaudited data

Implanet CEO Ludovic Lastennet said: : “In keeping with the last quarters of 2019, 2020 kicked off well for Implanet. January and February were marked by strong sales momentum. We posted 15% growth before the impact of Covid-19 in March and even outperformed our forecasts for the Knee business. Unfortunately, the Covid-19 pandemic has resulted in the global suspension of non-urgent surgeries.  When we take into account the extension of lockdown measures until at least mid-May, the impact on our business will continue into the second quarter. Our staff are poised to resume business as soon as possible, in order to retrieve the strong momentum we built at the start of the year.”


Upcoming financial events:  
   – 2020 H1 revenue, July 7th, 2020 after market close
   – 2020 H1 results, 15th September, 2020 after market close
 

A propos d’Implanet
Founded in 2007, Implanet is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around two product ranges, the latest generation JAZZ® implant, designed to improve the treatment of spinal pathologies requiring vertebral fusion surgery, and the MADISON implant designed for first-line prosthetic knee surgery. Implanet’s tried-and-tested orthopedic platform is based on product traceability. Protected by four families of international patents, JAZZ® and MADISON have obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark as well as the ANVISA authorization in Brazil. Implanet employs 36 staff and recorded 2019 sales of €7.4 million. For further information, please visit www.Implanet.com. Based near Bordeaux in France, Implanet established a US subsidiary in Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the equity line (OCA, OCAPI, BSA) and the number of shares outstanding, is available on its website:
http://www.implanet-invest.com/suivi-des-actions-80
www.implanet.com
To access the document in pdf please CLICK HERE
 
NEWCAP
Sandrine Boussard-Gallien
Investor relations
Phone nb.: 01 44 71 20 40
Email: implanet@newcap.eu

IMPLANET
Ludovic Lastennet
CEO
Phone nb.: 05 57 99 55 55
Email: investors@implanet.com

NEWCAP
Nicolas Merigeau
Media Relations
Phone nb.: 01 44 71 94 98
Email: nmerigeau@newcap.fr
Print Friendly, PDF & Email
Tags

Mike Adams

Mike Adams is a medical device sales leader with extensive clinical experience in spine and biologics and a nationwide distribution network built over the last 10+ years in the industry. He has held various leadership positions in healthcare and device including Distributor Partner, Hospital COO and Spine VP of Sales. He currently leads the commercialization strategy for OrthoSpine Partners and is a Distributor Principal at Novel Medical. Because of his unique career path, Mike has the ability to see the healthcare business from multiple perspectives making him passionate about building strategic partnerships that help reduce overall costs, drive innovation, and cultivate growth for new markets.

Related Articles

Back to top button
Close